

Cannabis use disorder: from neurobiology to treatment

Bernard Le Foll,^{1,2,3,4,5,6,7} Victor M. Tang,^{1,4,5,6} Sergio Rueda,^{1,4,5,6} Leanne V. Trick,⁸ and Isabelle Boileau^{2,4,5,6,9}

¹Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ²Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

³Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ⁴Campbell Family Mental Health Research Institute Centre for Addiction and Mental Health, Toronto, Ontario, Canada. ⁵Institute of Medical Sciences, ⁶Department of Psychiatry, and ⁷Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. ⁸Department of Psychology, Durham University, Durham, United Kingdom. ⁹Brain Health Imaging Centre, Toronto, Ontario, Canada.

Cannabis has been legalized for medical and recreational purposes in multiple countries. A large number of people are using cannabis and some will develop cannabis use disorder (CUD). There is a growing recognition that CUD requires specific interventions. This Review will cover this topic from a variety of perspectives, with a particular emphasis on neurobiological findings and innovative treatment approaches that are being pursued. We will first describe the epidemiology and burden of disease of CUD, including risk factors associated with CUD (both in terms of general risk and genetic risk variants). Neurobiological alterations identified in brain imaging studies will be presented. Several psychosocial interventions that are useful for the management of CUD, including motivational enhancement therapy, behavioral and cognitive therapy, and contingency management, will be covered. Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.

Epidemiology of cannabis use disorder

Cannabis ranks among the most used psychoactive substances globally, following only caffeine, alcohol, and tobacco (1). An estimated 219 million people between the ages of 15 and 64 years worldwide used cannabis in 2021, representing 4.3% of the global population in that age range (2). That same year, in the United States, a large, nationally representative survey estimated that 52.4 million people aged 12 years or older (18.7% of individuals in that age range) used cannabis in the past year (3). Furthermore, 16.3 million people (5.8% of individuals aged 12 years or older) met criteria for cannabis use disorder (CUD) (3), a chronic and relapsing condition characterized by persistent cannabis use despite adverse consequences (4). Although CUD is present across all age groups, it predominantly affects young adults. The proportion of young adults aged 18–25 years with past-year CUD (14.4%) was higher than the proportion of adolescents aged 12–17 years (4.8%) or adults 26 years or older (4.6%) (3). The median age of onset for CUD was 22 years (interquartile range [IQR], 19–29 years) (5). A younger age of initiation of cannabis use is associated with a faster progression to CUD, potentially leading to a more severe manifestation of the disorder (6, 7). Across all age groups, male individuals are also more likely to develop CUD (8–10), but some preliminary evidence suggests that female individuals progress to CUD more rapidly after initiation (8, 11).

The diagnostic criteria for CUD have changed over time. The DSM-5 Substance-Related Disorders Work Group changed the

structure of CUD from two disorders as defined in the DSM-IV (i.e., abuse and dependence) to a single disorder that combined 11 criteria, adding craving and withdrawal and removing substance-related legal problems (12). The latest edition, published in 2022 (DSM-5-TR), includes items related to impaired control over cannabis use, social impairments due to cannabis use, risky use of cannabis, and pharmacological indicators (13). Based on the number of criteria, CUD is now graded as mild (1–3 criteria), moderate (4–5 criteria), and severe (6 criteria). Because reports from national surveys and other large-scale population health studies still report findings based on previous DSM versions, it is important to keep in mind that these constructs include similar content but are organized differently.

The risk of developing CUD is influenced by various factors (1). A recent meta-analysis of observational studies with general population samples showed that people who have consumed cannabis (lifetime, recent, or regular use) have a 1 in 5 risk of developing CUD (14). The pooled prevalence estimate for CUD was 22% (95% CI: 18%–26%), and the risks were higher for younger people and for those who used cannabis daily or weekly. Modifiable factors influencing the onset of CUD include the frequency and duration of cannabis use. A recent meta-analysis pooling data from six prospective longitudinal studies found a log-linear dose-response relationship between four categorical levels of frequency of use (yearly, monthly, weekly, and daily) and the development of CUD (15). The risk of CUD increased 8-fold from a relative risk [RR] of 2.03 (95% CI, 1.85–2.22) for yearly use to a RR of 16.99 (95% CI, 11.80–24.46) for daily use. Multilevel modeling showed an absolute risk increase (ARI) from 3.5% (95% CI, 2.6–4.7) for past-year use to 36% (95% CI, 27.0–47.9) for daily use, suggesting that one-third of daily cannabis users are expected to develop CUD (15). This study showed not only that relatively infrequent use can result in CUD, but that the risk significantly increases with every additional level of use.

Conflict of interest: BLF has obtained funding and participated in the steering board of a clinical trial sponsored by Indivior. He has participated in a session of a National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada.

Copyright: © 2024, Le Foll et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: *J Clin Invest.* 2024;134(20):e172887.

<https://doi.org/10.1172/JCI172887>.

Table 1. Summary of recommendations from lower-risk cannabis use guidelines (ref. 37)

Behavior	Recommendation
Abstinence	1. The most effective way to avoid the risks of cannabis use is to abstain from use.
Age of initial use	2. Delaying cannabis use, at least until after adolescence, will reduce the likelihood or severity of adverse health outcomes.
Choice of cannabis products	3. Use products with low THC content and high CBD/THC ratios. 4. Synthetic cannabis products, such as K2 and Spice, should be avoided.
Cannabis use methods and practices	5. Avoid smoking burnt cannabis and choose safer inhalation methods, including vaporizers, e-cigarette devices, and edibles. 6. If cannabis is smoked, avoid harmful practices such as inhaling deeply or breath-holding.
Frequency and intensity of use	7. Avoid frequent or intensive use and limit consumption to occasional use, such as only one day a week or on weekends, or less.
Cannabis use and driving	8. Do not drive or operate other machinery for at least 6 hours after using cannabis. Combining alcohol and cannabis increases impairment and should be avoided.
Special-risk populations	9. People with a personal or family history of psychosis or substance use disorders, as well as pregnant women, should not use cannabis at all.
Combining risks or risk behaviors	10. Avoid combining any of the risk factors related to cannabis use. Multiple high-risk behaviors will amplify the likelihood or severity of adverse outcomes.

Reproduced from ref. 1 with permission from Springer Nature Limited, which retains rights to the reference information.

A comprehensive exploration of other plausible modifiable risk factors, such as amounts used or potency of Δ^9 -tetrahydrocannabinol (THC), the principal psychoactive component of cannabis, are difficult to carry out due to challenges in assessing the quantity and potency of THC content in cannabis products. Cannabis availability and use has been shifting from flower to processed products and from lower to higher THC products. Jurisdictions that have legalized cannabis have imposed minimal constraints on product availability such that there are no limits on THC concentrations (with the exception of edibles) (16). There have been recent increases in the use and availability of concentrates, with THC levels averaging 65%–70% but reaching levels as high as 90%–95% (17–20). Conversely, in cannabis flowers, THC concentration typically ranges between 16% and 21% but can go as high as 25%–30% (18, 21), and new lines of concentrate-infused flower products can go as high as 50%–55% (22). Despite the wider availability of high-THC products (23), there is limited experimental evidence on their effects (24). However, a recent systematic review reported low-quality evidence, suggesting that higher potency cannabis use was associated with an increased risk of CUD (25).

CUD frequently co-occurs with other psychiatric conditions, including various substance use disorders. Approximately three-quarters (73.8%) of patients diagnosed with CUD in primary care concurrently experience at least one other substance use disorder, predominantly those involving alcohol or tobacco (26). A recent systematic review focusing on large US population-based surveys reported large adjusted odds ratios (aORs) representing strong associations between past-year CUD and other substance use disorders, including any other substance use disorder (aOR = 9.3, 95% CI, 7.70–11.21), alcohol use disorder (aOR = 6.0, 95% CI, 5.10–6.97), and nicotine use disorder (aOR = 6.2, 95% CI, 5.24–7.34) (27). In addition, people diagnosed with CUD often exhibit other concurrent psychiatric disorders. The same review of large epidemiological studies also reported strong associations between past-year CUD and major depressive disorder (aOR = 2.8; 95% CI, 2.33–3.41), bipolar I disorder (aOR = 5.0; 95% CI, 3.65–6.75), any anxiety disorder (aOR = 2.8; 95% CI, 2.24–3.39), panic disorder (aOR = 3.3; 95% CI, 2.50–4.48), generalized anxiety

disorder (aOR = 3.7; 95% CI, 2.79–5.02), posttraumatic stress disorder (aOR = 4.3; 95% CI, 3.26–5.64), and any personality disorder (aOR = 4.8; 95% CI, 3.96–5.75) (27). As epidemiological studies cannot address causality, Mendelian randomization studies enable inference of causality between cannabis use and subsequent risk of psychiatric disorders (28). However, recent large studies have reported weak evidence for causal effect of cannabis use leading to increased risk of schizophrenia, while finding a more robust causal effect in the other direction (29, 30) (but see ref. 28). Other Mendelian randomization studies could not detect significant increase of risk of depression (31) or of bipolar disorder (32) induced by cannabis use. The presence of a co-occurring psychiatric disorder is linked to heightened severity of CUD and diminished responsiveness to treatment.

Burden of disease

Cannabis use contributes to a global health burden, although notably less than other psychoactive substances such as alcohol, tobacco, opioids, and stimulants. According to the Global Burden of Disease project, in 2016 CUDs resulted in an approximate 646,500 years of life lost to disability, with an age-standardized rate of 8.5 years per 100,000 persons (33). Despite an increase in cardiovascular disease mortality among US adults (34), the association between cannabis use and increased all-cause mortality remains uncertain (35). In Canada, the cannabis-attributable burden of disease in 2012 included 55,813 years of life lost due to disability, 10,533 years of life lost due to premature mortality, and 66,346 disability-adjusted life years overall. CUD was the most important single cause of cannabis-attributable burden of disease and the largest contributor to morbidity and years of life lost due to disability while cannabis-attributable lung cancer was the largest contributor to mortality followed by motor vehicle accidents (36). Guidelines have been developed to reduce the effect of cannabis on populations. Those cannabis use guidelines aimed at lowering risk have been endorsed by some public agencies and widely disseminated in Canada to reduce the impact of cannabis legalization using a public health framework (see Table 1) (37). It should be noted that high potency cannabis products may require specific measures to limit their effect on population (38).




Figure 1. Signaling by endogenous and exogenous cannabinoids modifies synaptic activity at multiple levels. (A) There are two known endocannabinoids, called anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Cannabis contains exogenous cannabinoids, including Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). **(B)** Endogenous cannabinoid release prevents overstimulation of neurons, modulates the release of various neurotransmitters such as GABA and glutamate, and has downstream effects, notably on dopaminergic transmission. The enzyme fatty acid amide hydrolase (FAAH) degrades anandamide. The enzyme MAGL regulates 2-AG. THC stimulates the cannabinoid system by binding to CB₁ and CB₂ receptors. Compared with signaling by endogenous cannabinoids (normal state), chronic cannabis use likely results in changes in various components of the endocannabinoid system (e.g., CB₁ and FAAH).

Pharmacology

The endocannabinoid system is present in the brain and periphery. THC primarily exerts its effects by acting as a partial agonist at the widely expressed Gi/Go protein-coupled cannabinoid receptor subtype 1 (CB₁) (39), but it is also a partial agonist for CB₂. The psychomimetic effects of THC are mediated by CB₁. Two endocannabinoid neurotransmitters have been identified: *N*-arachidonoylethanolamine (AEA or anandamide) and 2-arachidonoylglycerol (2-AG). There are enzymes that regulate the synthesis and the degradation of those endocannabinoids (e.g., fatty acid amide hydrolase [FAAH] degrades anandamide; see Figure 1). Certain characteristics of CUD are thought to emerge, in part, due to molecular adaptations in the brain resulting from repetitive exposure to cannabis, particularly its primary psychoactive compound, THC. One of the most noteworthy and consistently observed findings of adaptations to chronic cannabis use is the desensitization of CB₁ receptors in preclinical models (40). CB₁ desensitization refers to a reduced responsiveness or sensitivity of CB₁ receptors to the binding of cannabinoids over time. In preclinical models, this phenomenon has been associated with the development of significant tolerance to cannabis and to the severity of withdrawal symptoms. As well, the reduction in CB₁ signaling is believed to impact various physiological and behavioral processes, including appetite, memory and learning, mood, pain perception, and sleep (40). CB₁ desensitization in preclinical models may also alter neurotransmitter release patterns and synaptic communication (40).

Preclinical addiction models

Most drugs that have addictive potential are self-administered by laboratory animals (rodents or nonhuman primates) in experimental settings. However, initial attempts to develop a model of THC self-administration in rodents have been unsuccessful (41). The first clear intravenously THC self-administration has been obtained in squirrel monkeys previously trained to self-administer psychostimulant drug, but it has been also shown in naive animals (42, 43). Other preclinical models (e.g., conditioned place preference, drug discrimination, withdrawal paradigms, or intravenous self-administration of the direct CB₁ agonist WIN55,212-2) have been used to study the neurobiological mechanisms underlying CUD (see ref. 41 for a review). It is likely that the recent findings that vaporized cannabis extracts have reinforcing properties and are able to generate conditioned drug-seeking in rats will lead to further discoveries, as this will provide a useful and maybe more valid model to study relapse phenomenon (44).

The preclinical models that are used to study neurobiological mechanisms underlying CUD are also used to screen the utility of possible medications that can be tested in humans. Those studies notably point to a critical role of CB₁. Blockade of the CB₁ by the inverse agonist rimonabant prevented the elevation of dopamine induced by THC (45) but also THC taking (46, 47) and THC seeking (47) (see Figure 2A). However, chronic administration of rimonabant led to adverse psychiatric events, which resulted in its withdrawal from the market. Rimonabant was therefore used only for a few years in Europe and never marketed in North America (48). At the present time, various investigators are pursuing other




Figure 2. Selected pharmacological strategies under investigation for treatment of CUD. (A) CB₁ antagonists have demonstrated efficacy in preclinical models, with variable tolerability profiles. (B) CBD is the main nonpsychomimetic cannabis-derived compound. It has shown promising results in treatment of CUD. (C) Nabiximol (a 1:1 mixture of THC and CBD) may facilitate abstinence from cannabis in treatment-seeking patients, possibly by reducing withdrawal. (D) AEF0117, which blocks the intracellular signaling of CB₁, showed promise in decreasing cannabis use in a phase IIA study of volunteers with CUD.

ways of modulating the CB₁ transmission that may be devoid of the psychiatric side-effects of rimonabant. For example, AM4113 is a neutral CB₁ antagonist has been developed that is able to reduce THC taking and THC seeking in squirrel monkeys (47) (Figure 2A), but it appears to have a better tolerability profile (49). Pregnenolone is a drug that can block some effects of THC by acting as a signaling-specific inhibitor of CB₁ (CB₁-SSi) (50). A pregnenolone derivative drug called AEF0117, a more promising CB₁-SSi (51), reduces THC taking and THC seeking as well as THC-induced elevation of dopamine and various measures of impairment induced by THC (51). Negative allosteric modulators (NAMs) for CB₁ may have some therapeutic utility by blocking some effects of THC (but not all; for instance, there was no induction of withdrawal) (52). Cannabidiol is the major nonpsychomimetic compound derived from cannabis that has some potential for a range of neuropsychiatric disorders, including addictive disorders (53). However, the preclinical findings for CUD are mixed (45, 54–56).

Another approach consists of stimulating CB₁ transmission. This could be achieved by administration of CB₁ agonists such as THC or other derivatives (THC has been shown to be able to reverse pharmacologically induced cannabinoid withdrawal, ref. 57) or by modulating (57) the endocannabinoid tone, e.g., by blocking degradation processes. Blocking FAAH enzyme would enhance anandamide levels, while blocking MAGL enzyme would enhance 2-G levels. However, it appears that the two main endocannabinoids (2-AG and anandamide) may have opposite effects on their control of dopamine activity and reward seeking (58) and may modulate drug seeking differently (58–60). It is unclear how those two approaches would modulate THC taking, and THC seeking, and withdrawal at this point.

Other preclinical studies have identified various potential alternative approaches. Blocking mu opioid receptor signaling reduces elevation of dopamine induced by THC (45) and THC self-administration (61). Enhancing endogenous brain levels of kynurenic acid has a similar promising profile (62). It is likely that more targets will be identified as preclinical models become more widely used and with enhanced interest on this topic.

Heritability and genetic factors

The heritability of CUD has been recognized in early family-linkage and twin studies, with genetic factors accounting for 40%–70% of the risk of the disorder (63, 64). Genetic contributions have also been identified for cannabis use and cannabis use initiation (63), although genetic liability to CUD appears to only partially overlap with genetic correlates of cannabis use (65). Other phenotypes (e.g., subjective effects) may also be affected by gene variants (66, 67). GWAS approaches to identifying genes implicated in CUD initially did not show any single-nucleotide polymorphisms (SNPs) to be genome-wide significant (68), until an analysis of 14,754 patients identified significant SNP associations in 3 regions, which included an antisense transcript (rs143244591), and genes involved in calcium signaling (rs146091982) and growth cones during CNS development (rs77378271) (69). A subsequent study found a different cluster of associated SNPs on chromosome 10 in a cohort of individuals of European ancestry, and this was replicated in an independent cohort of African but not in European individuals (70). Demontis and colleagues (71) presented compelling findings in a GWAS that implicated a risk locus for CUD on chromosome 8 for the cholinergic receptor nicotinic $\alpha 2$ subunit gene (*CHRNA2*) that was then replicated in an independent sample. A recent larger GWAS further confirmed this finding with *CHRNA2* and also found a risk locus on chromosome 7 with *FOXP2* (65), which encodes a protein essential for synaptic plasticity and has been associated with externalizing behaviors and risk-taking behaviors (72). Furthermore, a finding consistent across studies is the shared genetic liability of CUD with other psychiatric illnesses such as major depressive disorder and schizophrenia (65, 69, 73). Most recently, a larger GWAS study identified some promising genes involved in CUD risk but also noted that this finding may be influenced by ancestry (see Table 2) (73). Overall, these findings indicate that CUD is likely a polygenic disorder, and more research is needed in this area.

Neurophysiology

On a functional neurophysiological level, it is possible to measure the functioning of the brain by recording electrical activity using electroencephalography (EEG). Individuals with CUD have abnor-

Table 2. Summary of GWAS findings reported in Levey et al., 2023 (ref. 73)

Population	n	No. of loci identified	Lead findings
European ancestry	42,281 cases	22	SNP near <i>CHRNA2</i> (rs56372821)
	843,744 controls	22	SNP near <i>CHRNA2</i> (rs56372821)
African ancestry	19,065 cases	2	SNP in <i>SLC36A2</i> intron (rs573117193)
	104,143 controls	2	SNP in <i>SLC36A2</i> intron (rs573117193)
Admixed American ancestry	2,774 cases	1	SNP near <i>LRR3B</i> (rs9815757)
	35,515 controls	1	SNP near <i>LRR3B</i> (rs9815757)
East Asian ancestry	194 cases	2	SNP in <i>SEMA6D</i> intron (rs78561048)
	6,649 controls	2	SNP in <i>SEMA6D</i> intron (rs78561048)

mal inhibitory control as measured by task-based EEG measures of frontal α asymmetry (74, 75). Furthermore, attentional biases toward cannabis-related cues demonstrated frontal EEG changes that were greater than that induced by both negative and neutral stimuli (76). Changes on frontal EEG related to cognitive deficits, such as reduced selective attention and processing speed, show that increasing frequency and chronicity of use is associated with greater abnormalities (77, 78). Interestingly, it has been shown that positivity on frontocentral electrode sites following reward receipt was increased in occasional cannabis users but not in individuals with CUD (79), suggesting that the progression from cannabis use to CUD may reflect a gradual hypoactivation to reward. On a network level, EEG has also been used to understand the differences in functional connectivity in the brains of individuals with CUD. Analyses of synchronization between distributed signals in the salience network and the central executive network revealed correlation with the degree of problematic cannabis use (80). In another study of spontaneous EEG activity at rest, CUD was shown to be associated with greater EEG complexity across brain regions, which reflects greater disorganization and noncoherent activity. Importantly, this finding was evident only in cannabis dependence and not in cannabis users who were not dependent (81).

The functioning of the brain has been also studied using transcranial magnetic stimulation. This approach uses electromagnetic pulses to depolarize focal areas of the cerebral cortex. Repetitive transcranial magnetic stimulation administration leads to a change in observed corticospinal excitability, which is a normal adaptive function of the brain. Cannabis use and CUD have been associated with a reduced capacity for cortical inhibition, a response known to involve γ -aminobutyric acid (GABA) receptors (74–78, 82–84).

fmRI studies

Various brain imaging studies have been conducted in regular cannabis users. A recent systematic review of fmRI studies looking at cue reactivity identified 18 studies (comprising 603 cannabis users and 315 individuals acting as controls) (85). Those studies indicated that exposure to cannabis-related stimuli versus neutral stimuli produces greater brain activation of three principal brain areas: the striatum, the prefrontal cortex, and the parietal cortex (85). Other areas such as hippocampus, amygdala, thalamus, and occipital cortex are also involved (85). These findings are consistent with the pattern of brain activations induced by drug-associated cues

in individuals with other addictions and support the notion that addiction processes recruit a vast number of brain areas to mediate cravings and drug-seeking behaviors (1, 86). The few studies that have explored the effect of chronic cannabis use on brain volumes (87) showed marginal effects that may be sex dependent (87) and much more limited than the impact of alcohol (88). Studies with larger samples are required.

PET studies

PET can be used to investigate the endocannabinoid system in the living human brain. PET probes have been developed that allow quantification of the CB₁ receptor and more recently the enzyme FAAH, which degrades the endogenous cannabinoid anandamide (1, 89). Some studies have investigated the regulation of those targets in individuals with CUD. Three published studies have investigated CB₁ receptor status in people with CUD ($n = \sim 50$ individuals with chronic cannabis use) using three different radiotracers: [¹¹C]OMAR, [¹⁸F]MK-9470, and [¹⁸F]FMPEP-d 2 (for a review of these tracers see, ref. 89). The findings are in line with preclinical data and suggest that chronic cannabis use is linked with lower CB₁ tracer binding (90–92). However, the studies are inconsistent regarding regional specificity of these effects. One study noted reduced CB₁ binding in cortical regions (91), another identifies lower binding affecting the hippocampus, amygdala, cingulate, and insula (92), while a third study showed a more global effect (90). A recovery in CB₁ receptor binding is observed following a four-week period of monitored cannabis abstinence (91). In these studies, the downregulation of CB₁ receptors was not conclusively linked to withdrawal symptoms. Instead, it was associated with the duration of cannabis use (91) and with increased anger and hostility in female cannabis users (92).

Limited preclinical investigations have explored the impact of chronic exposure to THC and subsequent withdrawal on the activity of FAAH, the enzyme responsible for metabolizing the major endocannabinoid anandamide. Most of these studies suggested that subchronic exposure to THC is associated with decreased FAAH activity (with a few exceptions) and elevated anandamide levels, particularly in the limbic forebrain but not in the striatum (93–95). The exact mechanism triggering this reduction in FAAH activity remains unclear and may involve a homeostatic response to CB₁ desensitization. Lowering FAAH activity can influence cannabis withdrawal (96), and understanding its status in the living human brain is crucial. Only two studies have investigated FAAH levels in individuals with chronic cannabis use (97, 98). Collectively testing around 23 individuals with CUD, these studies have demonstrated widespread reductions in FAAH binding among cannabis users, a phenomenon linked to the severity and chronicity of cannabis use.

Molecular imaging studies have also examined the dopaminergic system in individuals with CUD, given its pivotal role in reward processing and its implicated involvement in the development of addiction. PET imaging studies in the area of addiction have consistently reported dopamine system impairments, particularly in cases of psychostimulant use disorder (99). In CUD, PET studies of the dopamine system have utilized tracers target-

ing $D_{2/3}$ receptors, such as [^{11}C]raclopride and [^{11}C]-(-)-PHNO, along with [^{18}F]DOPA, a tracer that reflects dopamine synthesis. One study's cumulative findings suggested a decrease in dopamine synthesis among cannabis users, a phenomenon linked to more intensive cannabis use (99). Furthermore, two studies (100, 101) observed diminished stimulant-induced dopamine release in CUD, which contrasts with a third study that did not (102). Interestingly, in multiple studies, $D_{2/3}$ receptor status did not appear to be lower in CUD, according to studies by Sevy et al. (2008) (103), Volkow et al. 2014 (101), Tomasi et al. (2015) (104), and Urban, et al. (2012) (102).

Our understanding of the molecular underpinnings of CUD in living humans is currently restricted, especially regarding the connection between variability in the endocannabinoid system or dopamine markers and the manifestation of CUD symptoms and phenotypes. Further research endeavors utilizing novel molecular imaging techniques and comprehensive clinical assessments are needed to bridge these knowledge gaps.

Psychological interventions

In the absence of an approved pharmacotherapy for CUD, psychological and psychosocial interventions are currently the primary treatment options. These include motivational, cognitive, and behavioral approaches that were originally developed for the treatment of other substance use disorders and other individual, community, or family interventions (e.g., drug counseling, peer support, family therapy).

Previous meta-analytic reviews, including a Cochrane review (105–108), have pooled the findings of randomized controlled trials investigating the effectiveness of psychological treatments for CUD compared with active and inactive control conditions among treatment-seeking and nontreatment-seeking adults and young people. These reviews highlight the relatively small size of the evidence base (the number of relevant individual trials identified ranged from 5 to 23) but demonstrate that, overall, psychological interventions lead to modest reductions in the frequency and quantity of cannabis use (although evidence for improvements in other cannabis-related outcomes is less consistent). Psychological interventions identified in the studies included in these reviews include motivational enhancement therapy (MET), cognitive behavioral therapy (CBT), relapse prevention (a cognitive behavioral approach focused on prevention and management of lapses in abstinence), contingency management (CM), social support, mindfulness-based meditation, drug education and counseling, and various combinations of these interventions.

MET and CBT are the most widely researched individual psychological treatments for CUD. The aim of MET is to enhance motivation to stop or reduce cannabis use and increase self-efficacy through a combination of psychoeducation, goal setting, and developing plans for change, delivered within an empathic and nonjudgmental environment. CBT focuses on identifying both external triggers for cannabis use and unconstructive patterns of thought and behavior that maintain cannabis use and encourages the development of adaptive cognitive, behavioral, and emotional skills (such as coping strategies, problem-solving, and emotion regulation). Trials have shown that individually both MET and CBT lead to modest improvements in canna-

bis-related outcomes (including reduced frequency and quantity of cannabis use, a higher proportion of days of abstinence, fewer symptoms of dependence, fewer cannabis-related problems, and increased confidence to change cannabis use) among treatment seekers and nontreatment seekers (109–114), including individuals with psychiatric comorbidity (115). However, interventions that combine elements of both MET (to facilitate initial abstinence) and CBT (to support continued abstinence) are increasingly being recommended (116–119). Such suggestions are empirically supported, for example, by the large multisite trials among cannabis smokers with CUD reported by Babor and colleagues (112) and Hoch et al. (120, 121). These trials showed that MET and CBT, combined with case management and problem-solving, respectively, improved outcomes that include the frequency of cannabis use, abstinence rates, and symptom severity compared with a wait list control condition, with treatment benefits observed at follow-up appointments 3 to 15 months after initiation of treatment (although effect sizes decreased as the length of follow-up increased in both studies). In addition, a recent observational study showed that following a 12-week MET and CBT intervention delivered specifically in a real-life group treatment setting, the quantity and frequency of cannabis use were both reduced and other cannabis-related outcomes (e.g., cannabis-related problems, craving, anxiety and depressive symptoms) improved compared with those before treatment (122). Combined motivational and CBT-based approaches have also been shown to reduce the quantity and frequency of cannabis use when delivered remotely (123, 124).

The utility of CM for treating CUD has been explored. CM is a behavioral intervention that utilizes financial or other incentives to positively reinforce abstinence, or other desirable target behaviors such as treatment attendance, and has yielded beneficial effects in other substance use disorders with during treatment (although these appear to wane as time since treatment increases) (125). Currently, few studies have investigated the effectiveness of CM for CUD specifically. Trials that included a CM-only condition showed a reduction in self-reported and objectively measured abstinence in comparison to other active treatment and control conditions among individuals with CUD (109, 126, 127). A recent, small observational study suggested that remote delivery of a CM intervention may be a feasible and effective treatment approach (128). Several studies have used CM in combination with other active treatments (such as CBT and MET) to investigate possible cumulative treatment gains. Overall, most of these studies indicate that combination treatments that include CM are superior to individual interventions in individuals with CUD (127, 129), including among young adults involved in the criminal justice system (130) and adults with psychiatric comorbidities (131). However, consistent with findings in other substance use disorders (125), the improvements observed during individual or adjunct CM treatment tend to diminish relatively rapidly after the cessation of treatment. Thus, it is unclear to what extent CM promotes long-term abstinence from cannabis use.

While previous studies demonstrate that psychological interventions for treating CUD have positive effects on cannabis-related outcomes, methodological weaknesses that have been highlighted limit the generalizability of the findings. These

include high rates of dropout from treatment, heterogeneity in outcomes, and concerns about blinding of treatment allocation and outcome assessment (108). There are several other limitations of the existing evidence base. Chief among these are that effect sizes are often moderate at best (and tend to be highest where psychological treatments are compared against wait list or inactive control conditions, refs. 106, 108) and continuous abstinence rates are typically low, suggesting that although treatments are helpful in reducing cannabis use, they are not optimal for promoting complete abstinence. Additionally, the majority of existing studies have not included follow-up assessments beyond 12 months from treatment, and outcomes have tended to be most positive at the end of treatment or at short-term follow-up (e.g., refs. 112, 121). The effects of treatment over the long-term therefore require further investigation and it appears that sustained abstinence remains problematic. The addition of “booster” sessions after treatment may extend positive treatment effects. For example, following 9 sessions of MET and CBT, improved abstinence rates and fewer days of cannabis use were observed among adults with CUD who received maintenance checks at 1 and 4 months after treatment, compared with those in a “no-check” control condition (132).

The optimal duration and intensity of treatments also remains to be confirmed. Previous studies have delivered interventions of up to 14 sessions, although typically studies involving brief interventions (usually 1 or 2 sessions) have demonstrated the most inconsistent or null effects compared with inactive control conditions (133–135) and poorer outcomes compared with longer duration treatments (112). Further, poor rates of treatment retention in many studies (estimates suggest that as many as one-third of patients with substance use disorders including CUD drop out from psychosocial treatments, ref. 107) make it difficult to draw reliable conclusions about the number of sessions required to improve cannabis use outcomes.

To date, mechanisms of therapeutic change (136) and predictors of treatment outcomes have received scant attention in trials of psychological interventions for CUD. Preliminary findings from a recent observational study suggested that client factors including heavier cannabis use and elevated anxiety at entry to treatment may be linked to poorer treatment retention and greater posttreatment cannabis use (122). In addition, there were greater reductions in cannabis use in a trial of integrated MET and transdiagnostic CBT for both CUD and anxiety symptoms among dually diagnosed individuals, compared with standard MET and CBT, specifically among the subgroup with the most severe cannabis use at baseline (137). Better characterization of the factors that influence treatment effectiveness and engagement will be important in future studies as they could help to personalize and optimize treatments.

In summary, despite a relatively small evidence base, psychological interventions for CUD appear to be moderately effective, and combination treatments that both strengthen initial resolve to quit and support continued abstinence appear to be particularly helpful. However, helping individuals with CUD to achieve sustained abstinence remains problematic, and features of the intervention and characteristics of the population that are important for predicting treatment success remain poorly understood.

Pharmacological interventions

In comparison to other drugs of abuse, many fewer clinical trials have been conducted to test the utility of pharmacotherapies for CUD. However, this area is currently expanding (see ref. 138 for a review). Two Cochrane reviews have been performed summarizing the evidence (139, 140). It should be noted that no pharmacological interventions have been approved yet for treatment of CUD. Although the number of trials is limited, it appears that antidepressants, anxiolytics, or mood stabilizers have no or limited utility in managing CUD. The most promising agents appear to target the cannabinoid system. Notably, CB₁ agonists appear to be effective in attenuating the severity of cannabis withdrawal. This appears to be the case for direct CB₁ agonists such as dronabinol or nabilone (141, 142), for nabiximol (a combination of THC with cannabidiol) (143), and for FAAH inhibition (96). Managing cannabis withdrawal with pharmacological tools may be useful at the beginning of treatment in some patients with severe CUD for which the intensity of withdrawal may prevent behavioral change (see ref. 144 for a review). However, the long-term utility of direct cannabinoid agonists such as dronabinol is unclear (142). Recent promising studies suggest that nabiximol may be helpful in treatment-seeking patients trying to abstain from cannabis (145–148) (Figure 2B).

PF-04457845, a FAAH inhibitor, has been tested in a single-site study with promising results (96). Following those findings, a multicenter trial was performed, recruiting 116 individuals in the active group and 112 individuals in the placebo group (NCT03386487). Participants were randomized to either placebo or to 4 mg PF-04457845 for eight weeks. Although the results are not yet published, some findings have been posted on Clinicaltrials.gov, and it appears that the primary outcome was negative (no apparent change in the average number of times per day of self-reported cannabis consumption based on the time-line follow back).

Cannabidiol has also been tested alone for CUD and appeared to be superior to placebo in a phase II study (149) (Figure 2C).

To our knowledge, neutral antagonists (such as AM4113) or NAMs have not yet been tested in humans. Recently, the CB₁-SSi AEF0117 was tested in humans and was shown to reduce cannabis effects and cannabis self-administration in individuals with CUD in phase II studies (51) (Figure 2D).

Altogether, those findings suggest that, at this point, FAAH inhibitor may not be as effective as it was initially hoped. Nabiximols still have some important potential for CUD treatment. Among more recent drug in development, the CB₁-SSi AEF0117 seems to have some potential for development and should be tested in treatment-seeking patients. Drugs such as neutral CB₁ antagonist or NAMs may have some potential but would need to be tested in humans first. We can hope that one of those cannabinoid drugs may prove useful as medications for treating CUD in the future.

Other medications with potential utility include the anticonvulsant drugs gabapentin (NCT00395044) (150) and topiramate (NCT01110434) (151). Although other drugs have been tested in small-scale studies (e.g., opioid antagonists, n-acetylcysteine, oxytocin, and varenicline), it is unclear whether they have utility in treating CUD (140). The antipsychotic quetiapine may be useful in specific population, but its antipsychotic profile may limit its broad utility (152).

Conclusion

There have been tremendous advances in our understanding of CUD. Clearly, the determinants and risk factors are now better understood (1). We have also started to obtain insights into the neurobiological alterations associated with CUD. Advances in our preclinical models (41) and in the laboratory testing of cannabis self-administration (153) are allowing us to make faster progress on testing innovative treatment approaches for CUD (41). Harmonizing clinical trial outcome measures will be helpful for the field to compare results from clinical trials (154). The management of CUD relies on the usual approaches in addiction medicine (155), which so far are mostly psychosocial interventions. However, it seems likely that, in the coming years, pharmacological interventions will be validated and will complement psychosocial treatments delivered to patients with CUD (116). In addition,

neuromodulations approaches (e.g., repeated transcranial magnetic stimulation) that have shown some promises for substance use disorder treatment (156, 157) are being explored as treatment modality for CUD (158) and may represent an alternative to pharmacotherapies in the future.

Acknowledgments

BLF is supported by CAMH, Waypoint Centre for Mental Health Care, and a clinician-scientist award from the Department of Family and Community Medicine and a Chair in Addiction Psychiatry from the Department of Psychiatry of University of Toronto.

Address correspondence to: Bernard Le Foll, CAMH Translational Addiction Research Laboratory, 250 College Street, Toronto, Ontario M5T 1R8, Canada. Email: bernard.lefoll@camh.ca.

- Connor JP, et al. Cannabis use and cannabis use disorder. *Nat Rev Dis Primers*. 2021;7(1):16.
- United Nations Office on Drugs and Crime. World Drug Report 2023. <https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html>. Accessed August 23, 2024.
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health. <https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report>. Updated April 2023. Accessed August 23, 2024.
- Gorelick DA. Cannabis-related disorders and toxic effects. *N Engl J Med*. 2023;389(24):2267–2275.
- Solmi M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. *Mol Psychiatry*. 2022;27(1):281–295.
- Sherman BJ, et al. Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. *Drug Alcohol Depend*. 2021;218:108383.
- Le Strat Y, et al. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. *Accid Anal Prev*. 2015;76:1–5.
- Kerridge BT, et al. DSM-5 cannabis use disorder in the National Epidemiologic Survey on Alcohol and Related Conditions-III: Gender-specific profiles. *Addict Behav*. 2018;76:52–60.
- Khan SS, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. *Drug Alcohol Depend*. 2013;130(1–3):101–108.
- Grant JD, et al. A comparison of the latent class structure of cannabis problems among adult men and women who have used cannabis repeatedly. *Addiction*. 2006;101(8):1133–1142.
- Hernandez-Avila CA, et al. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. *Drug Alcohol Depend*. 2004;74(3):265–272.
- Hasin DS, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry*. 2013;170(8):834–851.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. American Psychiatric Association; 2022.
- Leung J, et al. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. *Addict Behav*. 2020;109:106479.
- Robinson T, et al. Identifying risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis. *Drug Alcohol Depend*. 2022;238:109582.
- Kilmer B, Pérez-Dávila S. Nine insights from 10 years of legal cannabis for nonmedical purposes. *Clin Ther*. 2023;45(6):496–505.
- Bidwell LC, et al. Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. *Addict Behav Rep*. 2018;8:102–106.
- Tassone F, et al. On offer to Ontario consumers three years after legalization: A profile of cannabis products, cannabinoid content, plant type, and prices. *Front Psychiatry*. 2023;14:1111330.
- Freeman TP, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. *Addiction*. 2021;116(5):1000–1010.
- Oregon Liquor & Cannabis Commission. Harvest, Price, & Sales Market Data. <https://www.oregon.gov/olcc/marijuana/Pages/Marijuana-Market-Data.aspx>. Accessed August 23, 2024.
- Smart R, et al. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. *Addiction*. 2017;112(12):2167–2177.
- Ontario Cannabis Store. Ontario Cannabis Store. <https://ocs.ca/>. Accessed August 23, 2024.
- Chandra S, et al. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). *Eur Arch Psychiatry Clin Neurosci*. 2019;269(1):5–15.
- Spindle TR, et al. Changing landscape of cannabis: novel products, formulations, and methods of administration. *Curr Opin Psychol*. 2019;30:98–102.
- Petrilli K, et al. Association of cannabis potency with mental ill health and addiction: a systematic review. *Lancet Psychiatry*. 2022;9(9):736–750.
- John WS, et al. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. *Drug Alcohol Depend*. 2018;187:79–87.
- Hasin D, Walsh C. Cannabis use, cannabis use disorder, and comorbid psychiatric illness: a narrative review. *J Clin Med*. 2021;10(1):15.
- Vaucher J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. *Mol Psychiatry*. 2018;23(5):1287–1292.
- Gage SH, et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. *Psychol Med*. 2017;47(5):971–980.
- Pasman JA, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. *Nat Neurosci*. 2018;21(9):1161–1170.
- Hodgson K, et al. Cannabis use, depression and self-harm: phenotypic and genetic relationships. *Addiction*. 2020;115(3):482–492.
- Jefsen OH, et al. Bipolar disorder and cannabis use: A bidirectional two-sample Mendelian randomization study. *Addict Biol*. 2021;26(6):e13030.
- GBD 2016 Alcohol Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Psychiatry*. 2018;5(12):987–1012.
- Sun Y, et al. Association of cannabis use with all-cause and cause-specific mortality among younger- and middle-aged U.S. Adults. *Am J Prev Med*. 2020;59(6):873–879.
- Calabria B, et al. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug Alcohol Rev*. 2010;29(3):318–330.
- Imtiaz S, et al. The burden of disease attributable to cannabis use in Canada in 2012. *Addiction*. 2016;111(4):653–662.
- Fischer B, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. *Am J Public Health*. 2017;107(8):e1–e12.
- Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis

- products: a narrative review and recommendations for public health. *Front Psychiatry*. 2020;11:591979.
39. Felder CC, et al. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. *Mol Pharmacol*. 1992;42(5):838–845.
 40. Gonzalez S, et al. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. *Pharmacol Biochem Behav*. 2005;81(2):300–318.
 41. Panlilio LV, et al. Screening medications for the treatment of cannabis use disorder. *Int Rev Neurobiol*. 2016;126:87–120.
 42. Tanda G, et al. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci*. 2000;3(11):1073–1074.
 43. Justinova Z, et al. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. *Psychopharmacology (Berl)*. 2003;169(2):135–140.
 44. Freels TG, et al. Vaporized cannabis extracts have reinforcing properties and support conditioned drug-seeking behavior in rats. *J Neurosci*. 2020;40(9):1897–1908.
 45. Tanda G, et al. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. *Science*. 1997;276(5321):2048–2050.
 46. Justinova Z, et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB1(1)-receptor antagonist rimonabant. *Neuropsychopharmacology*. 2008;33(12):2870–2877.
 47. Schindler CW, et al. Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys. *Neuropsychopharmacology*. 2016;41(9):2283–2293.
 48. Le Foll B, et al. The future of endocannabinoid-oriented clinical research after CB1 antagonists. *Psychopharmacology (Berl)*. 2009;205(1):171–174.
 49. Gueye AB, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. *Int J Neuropsychopharmacol*. 2016;19(12):pyw068.
 50. Vallee M, et al. Pregnenolone can protect the brain from cannabis intoxication. *Science*. 2014;343(6166):94–98.
 51. Haney M, et al. Signaling-specific inhibition of the CB₁ receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. *Nat Med*. 2023;29(6):1487–1499.
 52. Flavin A, et al. CB1 receptor negative allosteric modulators as a potential tool to reverse cannabinoid toxicity. *Molecules*. 2024;29(8):1881.
 53. Elsaid S, et al. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. *Prog Mol Biol Transl Sci*. 2019;167:25–75.
 54. Boggs DL, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ⁹-Tetrahydrocannabinol. *Neuropsychopharmacology*. 2018;43(1):142–154.
 55. Wakeford AGP, et al. The effects of cannabidiol (CBD) on Δ⁹-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats. *Exp Clin Psychopharmacol*. 2017;25(4):242–248.
 56. Pich EM, et al. Common neural substrates for the addictive properties of nicotine and cocaine. *Science*. 1997;275(5296):83–86.
 57. Lichtman AH, et al. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine. *Pharmacol Biochem Behav*. 2001;69(1-2):181–188.
 58. Peters KZ, et al. A brain on cannabinoids: the role of dopamine release in reward seeking and addiction. *Cold Spring Harb Perspect Med*. 2021;11(1):a039305.
 59. Trigo JM, Le Foll B. Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice. *Psychopharmacology (Berl)*. 2016;233(10):1815–1822.
 60. Forget B, et al. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB1(1) receptor blockade. *Psychopharmacology (Berl)*. 2009;205(4):613–624.
 61. Justinova Z, et al. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology (Berl)*. 2004;173(1-2):186–194.
 62. Justinova Z, et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. *Nat Neurosci*. 2013;16(11):1652–1661.
 63. Verweij KJ, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. *Addiction*. 2010;105(3):417–430.
 64. Lynskey MT, et al. An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. *Twin Res Hum Genet*. 2012;15(5):631–641.
 65. Johnson EC, et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. *Lancet Psychiatry*. 2020;7(12):1032–1045.
 66. Murphy T, et al. Influence of cannabinoid receptor 1 genetic variants on the subjective effects of smoked cannabis. *Int J Mol Sci*. 2021;22(14):7388.
 67. Bourgault Z, et al. Mu opioid receptor gene variant modulates subjective response to smoked cannabis. *Am J Transl Res*. 2022;14(1):623–632.
 68. Agrawal A, et al. A genome-wide association study of DSM-IV cannabis dependence. *Addict Biol*. 2011;16(3):514–518.
 69. Sherva R, et al. Genome-wide association study of cannabis dependence severity, novel risk variants, and shared genetic risks. *JAMA Psychiatry*. 2016;73(5):472–480.
 70. Agrawal A, et al. Genome-wide association study identifies a novel locus for cannabis dependence. *Mol Psychiatry*. 2018;23(5):1293–1302.
 71. Demontis D, et al. Genome-wide association study implicates CHRNA2 in cannabis use disorder. *Nat Neurosci*. 2019;22(7):1066–1074.
 72. Karlsson Linnér R, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat Genet*. 2019;51(2):245–257.
 73. Levey DF, et al. Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications. *Nat Genet*. 2023;55(12):2094–2103.
 74. Shevorykin A, et al. Frontal alpha asymmetry and inhibitory control among individuals with cannabis use disorders. *Brain Sci*. 2019;9(9):219.
 75. Smith EE, et al. Assessing and conceptualizing frontal EEG asymmetry: An updated primer on recording, processing, analyzing, and interpreting frontal alpha asymmetry. *Int J Psychophysiol*. 2017;111:98–114.
 76. Asmaro D, et al. Electrophysiological evidence of early attentional bias to drug-related pictures in chronic cannabis users. *Addict Behav*. 2014;39(1):114–121.
 77. Solowij N, et al. Differential impairments of selective attention due to frequency and duration of cannabis use. *Biol Psychiatry*. 1995;37(10):731–739.
 78. Skosnik PD, et al. The effect of cannabis use and gender on the visual steady state evoked potential. *Clin Neurophysiol*. 2006;117(1):144–156.
 79. Crane NA, et al. Cannabis users demonstrate enhanced neural reactivity to reward: An event-related potential and time-frequency EEG study. *Addict Behav*. 2021;113:106669.
 80. Imperatori C, et al. Increased resting state triple network functional connectivity in undergraduate problematic cannabis users: a preliminary EEG coherence study. *Brain Sci*. 2020;10(3):136.
 81. Laprevote V, et al. Association between increased EEG signal complexity and cannabis dependence. *Eur Neuropsychopharmacol*. 2017;27(12):1216–1222.
 82. Fitzgerald PB, et al. A transcranial magnetic stimulation study of the effects of cannabis use on motor cortical inhibition and excitability. *Neuropsychopharmacology*. 2009;34(11):2368–2375.
 83. Wobrock T, et al. Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. *Psychopharmacology (Berl)*. 2010;208(3):353–363.
 84. Martin-Rodriguez JF, et al. Impaired motor cortical plasticity associated with cannabis use disorder in young adults. *Addict Biol*. 2021;26(3):e12912.
 85. Sehl H, et al. Patterns of brain function associated with cannabis cue-reactivity in regular cannabis users: a systematic review of fMRI studies. *Psychopharmacology (Berl)*. 2021;238(10):2709–2728.
 86. Strang J, et al. Opioid use disorder. *Nat Rev Dis Primers*. 2020;6(1):3.
 87. Rossetti MG, et al. Sex and dependence related neuroanatomical differences in regular cannabis users: findings from the ENIGMA Addiction Working Group. *Transl Psychiatry*. 2021;11(1):272.
 88. Rossetti MG, et al. Gender-related neuroanatomical differences in alcohol dependence: findings from the ENIGMA Addiction Working Group. *Neuroimage Clin*. 2021;30:102636.
 89. Varlow C, et al. Classics in neuroimaging: imaging the endocannabinoid pathway with PET. *ACS Chem Neurosci*. 2020;11(13):1855–1862.
 90. Ceccarini J, et al. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor avail-

- ability in chronic cannabis users. *Addict Biol.* 2015;20(2):357–367.
91. Hirvonen J, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry.* 2012;17(6):642–649.
 92. Spindle TR, et al. Brain imaging of cannabinoid type 1 (CB₁) receptors in women with cannabis use disorder and male and female healthy controls. *Addict Biol.* 2021;26(6):e13061.
 93. Di Marzo V, et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. *J Neurochem.* 2000;74(4):1627–1635.
 94. Gonzalez S, et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. *Drug Alcohol Depend.* 2004;74(2):159–170.
 95. De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol.* 2011;163(7):1479–1494.
 96. D'Souza DC, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. *Lancet Psychiatry.* 2019;6(1):35–45.
 97. Boileau I, et al. Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [¹¹C]CURB. *Biol Psychiatry.* 2016;80(9):691–701.
 98. Jacobson MR, et al. Fatty acid amide hydrolase is lower in young cannabis users. *Addict Biol.* 2021;26(1):e12872.
 99. Nutt DJ, et al. The dopamine theory of addiction: 40 years of highs and lows. *Nat Rev Neurosci.* 2015;16(5):305–312.
 100. van de Giessen E, et al. Deficits in striatal dopamine release in cannabis dependence. *Mol Psychiatry.* 2017;22(1):68–75.
 101. Volkow ND, et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. *Proc Natl Acad Sci U S A.* 2014;111(30):E3149–E3156.
 102. Urban NB, et al. Dopamine release in chronic cannabis users: a [¹¹C]raclopride positron emission tomography study. *Biol Psychiatry.* 2012;71(8):677–683.
 103. Sevy S, et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. *Psychopharmacology (Berl).* 2008;197(4):549–556.
 104. Tomasi D, et al. Balanced modulation of striatal activation from D2 /D3 receptors in caudate and ventral striatum: Disruption in cannabis abusers. *Hum Brain Mapp.* 2015;36(8):3154–3166.
 105. Bender K, et al. A meta-analysis of interventions to reduce adolescent cannabis use. *Res Soc Work Pract.* 2011;21(2):153.
 106. Davis ML, et al. Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. *Eval Health Prof.* 2015;38(1):94–114.
 107. Dutra L, et al. A meta-analytic review of psychosocial interventions for substance use disorders. *Am J Psychiatry.* 2008;165(2):179–187.
 108. Gates PJ, et al. Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev.* 2016;2016(5):CD005336.
 109. Carroll KM, et al. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. *Addiction.* 2012;107(9):1650–1659.
 110. Copeland J, et al. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. *J Subst Abuse Treat.* 2001;21(2):55–64; discussion 65.
 111. Stephens RS, et al. Comparison of extended versus brief treatments for marijuana use. *J Consult Clin Psychol.* 2000;68(5):898–908.
 112. Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. *J Consult Clin Psychol.* 2004;72(3):455–466.
 113. Bonsack C, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. *Psychother Psychosom.* 2011;80(5):287–297.
 114. Lee CM, et al. Indicated prevention for college student marijuana use: a randomized controlled trial. *J Consult Clin Psychol.* 2013;81(4):702–709.
 115. González-Ortega I, et al. Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: a 1-year randomized controlled trial. *Int J Environ Res Public Health.* 2022;19(12):7325.
 116. Sabioni P, Le Foll B. Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. *F1000Res.* 2018;7:173.
 117. Budney AJ, et al. Marijuana dependence and its treatment. *Addict Sci Clin Pract.* 2007;4(1):4–16.
 118. Roffman R, Stephens RS. *Cannabis Dependence: Its Nature, Consequences and Treatment.* Cambridge University Press; 2006.
 119. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. *Psychiatr Clin North Am.* 2012;35(2):309–326.
 120. Hoch E, et al. Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). *Eur Neuropsychopharmacol.* 2012;22(4):267–280.
 121. Hoch E, et al. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. *Drug Alcohol Depend.* 2014;134:185–193.
 122. Trick L, et al. Implementation and preliminary evaluation of a 12-week cognitive behavioural and motivational enhancement group therapy for cannabis use disorder. *Subst Abuse.* 2023;17:11782218231205840.
 123. Gates PJ, et al. Randomized controlled trial of a novel cannabis use intervention delivered by telephone. *Addiction.* 2012;107(12):2149–2158.
 124. Rooke S, et al. Effectiveness of a self-guided web-based cannabis treatment program: randomized controlled trial. *J Med Internet Res.* 2013;15(2):e26.
 125. Davis DR, et al. A review of the literature on contingency management in the treatment of substance use disorders, 2009–2014. *Prev Med.* 2016;92:36–46.
 126. Kadden RM, et al. Abstinence rates following behavioral treatments for marijuana dependence. *Addict Behav.* 2007;32(6):1220–1236.
 127. Budney AJ, et al. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. *J Consult Clin Psychol.* 2006;74(2):307–316.
 128. Beckham JC, et al. Development of mobile contingency management for cannabis use reduction. *Behav Ther.* 2023;55(1):1–13.
 129. Budney AJ, et al. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. *J Consult Clin Psychol.* 2000;68(6):1051–1061.
 130. Carroll KM, et al. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. *J Consult Clin Psychol.* 2006;74(5):955–966.
 131. Rodas JD, et al. Contingency management for treatment of cannabis use disorder in co-occurring mental health disorders: a systematic review. *Brain Sci.* 2022;13(1):36.
 132. Walker DD, et al. Maintenance check-ups following treatment for cannabis dependence. *J Subst Abuse Treat.* 2015;56:11–15.
 133. Stein LA, et al. Motivational interviewing for incarcerated adolescents: effects of depressive symptoms on reducing alcohol and marijuana use after release. *J Stud Alcohol Drugs.* 2011;72(3):497–506.
 134. Stein MD, et al. A brief marijuana intervention for non-treatment-seeking young adult women. *J Subst Abuse Treat.* 2011;40(2):189–198.
 135. Imtiaz S, et al. Brief interventions for cannabis use in healthcare settings: systematic review and meta-analyses of randomized trials. *J Addict Med.* 2020;14(1):78–88.
 136. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and future outlook. *Pharmacotherapy.* 2016;36(5):511–535.
 137. Buckner JD, et al. Integrated cognitive-behavioral therapy for comorbid cannabis use and anxiety disorders: The impact of severity of cannabis use. *Exp Clin Psychopharmacol.* 2021;29(3):272–278.
 138. Nielsen S, et al. Pharmacotherapies for cannabis use disorders: clinical challenges and promising therapeutic agents. *Handb Exp Pharmacol.* 2020;258:355–372.
 139. Marshall K, et al. Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev.* 2014;12(12):CD008940.
 140. Nielsen S, et al. Pharmacotherapies for cannabis dependence. *Cochrane Database Syst Rev.* 2019;1(1):CD008940.
 141. Herrmann ES, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. *Psychopharmacology (Berl).* 2016;233(13):2469–2478.
 142. Levin FR, et al. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend.* 2011;116(1–3):142–150.
 143. Trigo JM, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and

- cravings. *Drug Alcohol Depend.* 2016;161:298–306.
144. Connor JB, et al. Clinical management of cannabis withdrawal. *Addiction.* 2022;117(7):2075–2095.
 145. Trigo JM, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. *PLoS One.* 2018;13(1):e0190768.
 146. Lintzeris N, et al. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. *Drug Alcohol Depend.* 2020;215:108220.
 147. Montebello M, et al. Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: findings from a nabiximols versus placebo randomised controlled trial. *Drug Alcohol Depend.* 2022;234:109388.
 148. Allsop DJ, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. *JAMA Psychiatry.* 2014;71(3):281–291.
 149. Freeman TP, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. *Lancet Psychiatry.* 2020;7(10):865–874.
 150. Mason BJ, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. *Neuropsychopharmacology.* 2012;37(7):1689–1698.
 151. Miranda R, Jr. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. *Addict Biol.* 2017;22(3):779–790.
 152. Mariani JJ, et al. Quetiapine treatment for cannabis use disorder. *Drug Alcohol Depend.* 2021;218:108366.
 153. Xiao KB, et al. Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies. *Psychopharmacology (Berl).* 2023;240(7):1393–1415.
 154. Loflin MJE, et al. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. *Drug Alcohol Depend.* 2020;212:107993.
 155. Levesque A, Le Foll B. When and how to treat possible cannabis use disorder. *Med Clin North Am.* 2018;102(4):667–681.
 156. Mehta DD, et al. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. *Neuropsychopharmacology.* 2024;49(4):649–680.
 157. Ibrahim C, et al. The insula: a brain stimulation target for the treatment of addiction. *Front Pharmacol.* 2019;10:720.
 158. Ngoy A, et al. Neuromodulation for cannabis use: a scoping review. *Brain Sci.* 2024;14(4):356.
 159. Guzmán M. Cannabinoids: potential anticancer agents. *Nat Rev Cancer.* 2003;3(10):745–755.